Clinical Trial Update: Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether liposomal prostaglandin E1 (Lipo-PGE1) reduces myocardial injury after percutaneous coronary intervention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease
• Myocardial Reperfusion Injury

Drugs mentioned

• Lipo-PGE1 (prostaglandin E1 (liposomal formulation))

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Prostaglandin E1, Percutaneous Coronary Intervention | Phase 3 | Status: UNKNOWN